About Intravenous Immunoglobulins
Immunoglobulins are glycoprotein molecules produced by plasma cells. They are a critical part of a body's immune response and they do so by specifically recognizing and binding to microbes and destroying them. These immunoglobulins are produced by a body naturally, but due to some genetic or infectious diseases, the natural production of immunoglobulin is inhibited, resulting in an immune-compromised condition.
Technavio’s analysts forecast the global intravenous immunoglobulins market to grow at a CAGR of 7.62% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global intravenous immunoglobulins market for 2017-2021. To calculate the market size, the report considers sales from both generic and branded drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Intravenous Immunoglobulins Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• CSL Behring
• Grifols
• Octapharma
• Shire
Other prominent vendors
• ADMA Biologics
• Bayer
• Bharat Serum and Vaccines
• Biotest AG
• China Biologic Products
• Hualan Biological Engineering
• Kedrion Biopharma
• LFB Group
• Sanquin
Market driver
• Growing number of fractionating units
• For a full, detailed list, view our report
Market challenge
• Complex and cost-intensive manufacturing
• For a full, detailed list, view our report
Market trend
• Monetary support to plasma donors
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: An overview of diseases treated using intravenous immunoglobulins
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by Therapy area
• Global intravenous immunoglobulins market by neurology
• Global intravenous immunoglobins market for hematology
• Global intravenous immunoglobins market for immunology
• Global intravenous immunoglobins market for others
PART 09: Geographical segmentation
• Intravenous immunoglobulins market in Americas
• Intravenous immunoglobulins market in EMEA
• Intravenous immunoglobulins market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Market challenges
PART 12: Market trends
• Shift in manufacturing facilities to low-cost regions
• Monetary support to plasma donors
PART 13: Vendor landscape
• Competitive scenario
PART 14: Key vendor analysis
• CSL Behring
• Grifols
• Octapharma
• Shire
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Major diseases treated using intravenous immunoglobins therapy
Exhibit 02: Global intravenous immunoglobulins market snapshot
Exhibit 03: Global intravenous immunoglobins market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis in global intravenous immunoglobulins market
Exhibit 05: Five forces analysis
Exhibit 06: Pipeline analysis of vendors
Exhibit 07: Key clinical trials 2016
Exhibit 08: Global intravenous immunoglobulin market by therapy area 2016
Exhibit 09: Global intravenous immunoglobins market for neurology 2016-2021 ($ million)
Exhibit 10: Global intravenous immunoglobins market by hematology 2016-2021 ($ million)
Exhibit 11: Global intravenous immunoglobins market for immunology 2016-2021 ($ million)
Exhibit 12: Global intravenous immunoglobins market for others 2016-2021 ($ million)
Exhibit 13: Global intravenous immunoglobulin market by geography 2016 and 2021
Exhibit 14: Global intravenous immunoglobulin market by geography 2016-2021 ($ millions)
Exhibit 15: Market scenario in Americas
Exhibit 16: Intravenous immunoglobulins market in Americas 2016-2021 ($ millions)
Exhibit 17: North America: Percentage of global fractionation capacities 1999-2012
Exhibit 18: Market Scenario in EMEA
Exhibit 19: Intravenous immunoglobulins market in EMEA 2016-2021 ($ million)
Exhibit 20: Europe: percentage of global fractionation capacities 1999-2012
Exhibit 21: Market Scenario in APAC
Exhibit 22: Intravenous immunoglobulins market in APAC 2016-2021 ($ million)
Exhibit 23: APAC: Percentage of global fractionation capacities 1999-2012
Exhibit 24: Fractionation capacities of key vendors
Exhibit 25: Factors contributing to overall cost of immunoglobulin production
Exhibit 26: Various side-effects associated with immunoglobulin therapy
Exhibit 27: Regulatory requirements for TGA approval
Exhibit 28: Fractionating capacities globally 2007 and 2012
Exhibit 29: Competitive structure analysis of global intravenous immunoglobulins market 2016
Exhibit 30: Competitive factors in global intravenous immunoglobulins market
Exhibit 31: Market penetration of manufacturers of intravenous immunoglobulins worldwide 2016
Exhibit 32: Strategic success factors of companies in global intravenous immunoglobulins market
Exhibit 33: Key news in IVIG market
Exhibit 34: CSL Behring: Key Highlights
Exhibit 35: CSL Behring: Strength assessment
Exhibit 36: CSL Behring: Strategy assessment
Exhibit 37: CSL Behring: Opportunity assessment
Exhibit 38: Grifols: Key highlights
Exhibit 39: Grifols: Strength assessment
Exhibit 40: Grifols: Strategy assessment
Exhibit 41: Grifols: Opportunity assessment
Exhibit 42: Octapharma: Key highlights
Exhibit 43: Octapharma: Strength assessment
Exhibit 44: Octapharma: Strategy assessment
Exhibit 45: Octapharma: Opportunity assessment
Exhibit 46: Shire: Key highlights
Exhibit 47: Shire: Strength assessment
Exhibit 48: Shire: Strategy assessment
Exhibit 49: Shire: Opportunity assessment
